DDInter1424 DDInter1628
Pentosan polysulfate is a sulfated pentosyl polysaccharide with heparin-like properties.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Pentosan polysulfate {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Pentosan polysulfate {u} (Compound) binds {v} (Gene) FGF1
FGF1 {u} (Gene) is associated with {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Pentosan polysulfate {u} (Compound) binds {v} (Gene) FGF4
FGF4 {u} (Gene) covaries with {v} (Gene) RPS6KA6
RPS6KA6 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Pentosan polysulfate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Dasatinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Pentosan polysulfate {u} (Compound) binds {v} (Gene) FGF2
FGF2 {u} (Gene) regulates {v} (Gene) KIAA1033
KIAA1033 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Pentosan polysulfate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enoxaparin
Enoxaparin {u} (Compound) causes {v} (Side Effect) Haemorrhage intracranial
Haemorrhage intracranial {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Pentosan polysulfate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Dasatinib {u} (Compound) binds {v} (Gene) MAP3K19
MAP3K19 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Pentosan polysulfate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) upregulates {v} (Gene) HDAC6
HDAC6 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Pentosan polysulfate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) upregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Pentosan polysulfate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) downregulates {v} (Gene) URB2
URB2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Pentosan polysulfate (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Pentosan polysulfate (Compound) binds FGF1 (Gene) and FGF1 (Gene) is associated with hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Pentosan polysulfate (Compound) binds FGF4 (Gene) and FGF4 (Gene) covaries with RPS6KA6 (Gene) and RPS6KA6 (Gene) is bound by Ruxolitinib (Compound)
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Pentosan polysulfate (Compound) binds FGF2 (Gene) and FGF2 (Gene) regulates KIAA1033 (Gene) and KIAA1033 (Gene) is downregulated by Ruxolitinib (Compound)
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin and Enoxaparin (Compound) causes Haemorrhage intracranial (Side Effect) and Haemorrhage intracranial (Side Effect) is caused by Ruxolitinib (Compound)
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib (Compound) binds MAP3K19 (Gene) and MAP3K19 (Gene) is bound by Ruxolitinib (Compound)
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) upregulates HDAC6 (Gene) and HDAC6 (Gene) is downregulated by Ruxolitinib (Compound)
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) upregulates PLK1 (Gene) and PLK1 (Gene) is bound by Ruxolitinib (Compound)
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) downregulates URB2 (Gene) and URB2 (Gene) is upregulated by Ruxolitinib (Compound)